Browse DYRK1A

Summary
SymbolDYRK1A
Namedual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A
Aliases DYRK1; DYRK; MNBH; HP86; MNB; MRD7; MNB/DYRK protein kinase; dual specificity YAK1-related kinase; hMNB; mnb ......
Chromosomal Location21q22.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Nucleus speckle
Domain PF00069 Protein kinase domain
Function

Dual-specificity kinase which possesses both serine/threonine and tyrosine kinase activities. May play a role in a signaling pathway regulating nuclear functions of cell proliferation. Modulates alternative splicing by phosphorylating the splice factor SRSF6 (By similarity). Exhibits a substrate preference for proline at position P+1 and arginine at position P-3. Has pro-survival function and negatively regulates the apoptotic process. Promotes cell survival upon genotoxic stress through phosphorylation of SIRT1. This in turn inhibits TP53 activity and apoptosis (By similarity).

> Gene Ontology
 
Biological Process GO:0000375 RNA splicing, via transesterification reactions
GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile
GO:0000380 alternative mRNA splicing, via spliceosome
GO:0000381 regulation of alternative mRNA splicing, via spliceosome
GO:0000398 mRNA splicing, via spliceosome
GO:0006397 mRNA processing
GO:0006476 protein deacetylation
GO:0007623 circadian rhythm
GO:0008380 RNA splicing
GO:0018105 peptidyl-serine phosphorylation
GO:0018107 peptidyl-threonine phosphorylation
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018209 peptidyl-serine modification
GO:0018210 peptidyl-threonine modification
GO:0018212 peptidyl-tyrosine modification
GO:0030330 DNA damage response, signal transduction by p53 class mediator
GO:0033119 negative regulation of RNA splicing
GO:0035601 protein deacylation
GO:0042770 signal transduction in response to DNA damage
GO:0043484 regulation of RNA splicing
GO:0043516 regulation of DNA damage response, signal transduction by p53 class mediator
GO:0043518 negative regulation of DNA damage response, signal transduction by p53 class mediator
GO:0046777 protein autophosphorylation
GO:0048024 regulation of mRNA splicing, via spliceosome
GO:0048025 negative regulation of mRNA splicing, via spliceosome
GO:0048511 rhythmic process
GO:0050684 regulation of mRNA processing
GO:0050686 negative regulation of mRNA processing
GO:0072331 signal transduction by p53 class mediator
GO:0090311 regulation of protein deacetylation
GO:0090312 positive regulation of protein deacetylation
GO:0098732 macromolecule deacylation
GO:1901796 regulation of signal transduction by p53 class mediator
GO:1901797 negative regulation of signal transduction by p53 class mediator
GO:1902532 negative regulation of intracellular signal transduction
GO:1903311 regulation of mRNA metabolic process
GO:1903312 negative regulation of mRNA metabolic process
GO:2001020 regulation of response to DNA damage stimulus
GO:2001021 negative regulation of response to DNA damage stimulus
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004712 protein serine/threonine/tyrosine kinase activity
GO:0004713 protein tyrosine kinase activity
GO:0004715 non-membrane spanning protein tyrosine kinase activity
GO:0043621 protein self-association
GO:0048156 tau protein binding
Cellular Component GO:0016604 nuclear body
GO:0016607 nuclear speck
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-1538133: G0 and Early G1
R-HSA-453279: Mitotic G1-G1/S phases
Summary
SymbolDYRK1A
Namedual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A
Aliases DYRK1; DYRK; MNBH; HP86; MNB; MRD7; MNB/DYRK protein kinase; dual specificity YAK1-related kinase; hMNB; mnb ......
Chromosomal Location21q22.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DYRK1A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolDYRK1A
Namedual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A
Aliases DYRK1; DYRK; MNBH; HP86; MNB; MRD7; MNB/DYRK protein kinase; dual specificity YAK1-related kinase; hMNB; mnb ......
Chromosomal Location21q22.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DYRK1A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.54 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolDYRK1A
Namedual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A
Aliases DYRK1; DYRK; MNBH; HP86; MNB; MRD7; MNB/DYRK protein kinase; dual specificity YAK1-related kinase; hMNB; mnb ......
Chromosomal Location21q22.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DYRK1A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1350.527
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1310.938
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1340.917
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1580.615
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.150.953
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.5490.863
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1340.729
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0730.968
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3650.856
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6780.553
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2510.459
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1340.0097
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of DYRK1A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472514.310.71
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolDYRK1A
Namedual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A
Aliases DYRK1; DYRK; MNBH; HP86; MNB; MRD7; MNB/DYRK protein kinase; dual specificity YAK1-related kinase; hMNB; mnb ......
Chromosomal Location21q22.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DYRK1A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDYRK1A
Namedual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A
Aliases DYRK1; DYRK; MNBH; HP86; MNB; MRD7; MNB/DYRK protein kinase; dual specificity YAK1-related kinase; hMNB; mnb ......
Chromosomal Location21q22.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DYRK1A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DYRK1A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDYRK1A
Namedual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A
Aliases DYRK1; DYRK; MNBH; HP86; MNB; MRD7; MNB/DYRK protein kinase; dual specificity YAK1-related kinase; hMNB; mnb ......
Chromosomal Location21q22.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DYRK1A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDYRK1A
Namedual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A
Aliases DYRK1; DYRK; MNBH; HP86; MNB; MRD7; MNB/DYRK protein kinase; dual specificity YAK1-related kinase; hMNB; mnb ......
Chromosomal Location21q22.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DYRK1A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDYRK1A
Namedual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A
Aliases DYRK1; DYRK; MNBH; HP86; MNB; MRD7; MNB/DYRK protein kinase; dual specificity YAK1-related kinase; hMNB; mnb ......
Chromosomal Location21q22.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DYRK1A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDYRK1A
Namedual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A
Aliases DYRK1; DYRK; MNBH; HP86; MNB; MRD7; MNB/DYRK protein kinase; dual specificity YAK1-related kinase; hMNB; mnb ......
Chromosomal Location21q22.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DYRK1A collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting DYRK1A.
ID Name Drug Type Targets #Targets
DB07608N-(5-{[(2S)-4-amino-2-(3-chlorophenyl)butanoyl]amino}-1H-indazol-3-yl)benzamideSmall MoleculeDYRK1A1